Abstract 17663: Circulating Mir-221-3p is a Novel Predictive Biomarker in Patients With Acute Myocardial Infarction
Introduction: MicroRNAs (miRNAs) regulate gene expression at the post-transcriptional level. Recent studies have reported circulating miRNAs as novel biomarkers in heart failure, diabetes mellitus, stroke, and acute pulmonary embolism. There are some studies in the literature evaluating a diagnostic role of miRNAs in acute myocardial infarction (AMI) with different expression levels and controversial results. Hence, there is still a need for new miRNA based studies to improve early and precise diagnosis of this disease.
Hypothesis: The aims of this study were 1) to compare the plasma expression levels of miRNAs in patients with AMI and control subjects 2) to investigate the relations of miRNAs with troponin I, SYNTAX score and post-MI left ventricular functions and 3) to evaluate miRNAs potential to be used as novel predictive biomarkers for AMI.
Methods: Twenty seven consecutive patients, who admitted to emergency department between January-December 2013 with acute chest pain and/or dyspnea and diagnosed with AMI, and 16 healthy control subjects were included in this study. miRNA profiling was performed by using real time polymerase chain reaction. A miRNA with a fold-change of ≥ 2 was considered as an upregulated miRNA, while a miRNA with a fold -change of ≤ 0.5 was considered as a downregulated miRNA.
Results: miR-221-3p were the most deregulated miRNAs with a fold change of 3.89 (p=0.003). It was significantly positively correlated with both troponin (r=0.503, p=0.001) and SYNTAX Score (r=0.413, p=0.036). Moreover, miR221 was found to be significantly inversely correlated with left ventricular ejection fraction (r=0.-280, p=0.039). miR-221-3p was the most prominent biomarker candidate for prediction of AMI with an area under curve (AUC) level of 0.881 (95% confidence interval: 0.774-0.987; p=0.002), which was very close to peak level of Troponin (AUC: 0.954; 95% CI: 0.892-1.000; <0.001).
Conclusions: The present study is the first to report an increased expression levels of miR-221-3p in AMI. Since miR-221-3p has a high discriminative value and significant relations with Troponin, SYNTAX score and left ventricular systolic function, it may be a potential and promising novel biomarker for early and precise diagnosis and severity of AMI.
Author Disclosures: E. Coskunpinar: None. H.A. Cakmak: None. A. Kalkan: None. N. Tiryakioglu: None. M. Erturk: None. Z. Ongen: None.
- © 2016 by American Heart Association, Inc.